Abpro Holdings, Inc Common Stock (ABP)

• Market cap: $26.5M
• 1 day: -16.76%
• 5 days: -32.89%
• 1 month: -46.87%
• 3 months: -78.84%
• 6 months: -89.78%
• Year to date: -67.52%
• 1 year: -89.78%
• 5 years: -89.78%
• 10 years: -89.78%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

3.06% more ownership

Funds ownership: 0% [Q3] → 3.06% (+3.06%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 684% upside
• Avg. target: $4 684% upside
• High target: $4 684% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 18% 1-year accuracy 6 / 34 met price target

684% upside $4

Buy Initiated

24 Feb 2025